Welcome to our dedicated page for SeaStar Medical Holding news (Ticker: ICU), a resource for investors and traders seeking the latest updates and insights on SeaStar Medical Holding stock.
SeaStar Medical Holding Corporation develops and commercializes extracorporeal medical-device therapies for critically ill patients with organ failure driven by hyperinflammation. Its first commercial product, QUELIMMUNE (SCD-PED), is based on the company’s Selective Cytopheretic Device technology and is FDA approved for pediatric acute kidney injury associated with sepsis or a septic condition in patients requiring renal replacement therapy.
Recurring company updates cover QUELIMMUNE adoption by children’s hospitals, SAVE post-approval registry data, publications and conference presentations, and financial results. News also addresses clinical development of SCD therapy in adult acute kidney injury requiring continuous renal replacement therapy and in cardio-renal indications, as well as FDA Breakthrough Device and Humanitarian Device pathways for additional SCD uses.
SeaStar Medical, trading under the ticker ICU, has begun its journey on the Nasdaq following a successful business combination with LMF Acquisition Opportunities. The company aims to advance its Selective Cytopheretic Device (SCD) to treat hyperinflammation, focusing on pediatric and adult Acute Kidney Injury (AKI). Regulatory milestones include potential FDA approval for pediatric AKI in Q1 2023 and a pivotal trial in adult AKI also commencing in Q1 2023. The company's innovative therapy is designed to neutralize pro-inflammatory cells, aiming to significantly improve patient outcomes.